Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher R Frei

Showing results (11-20 of 127) with videos related to

Pageof 13
Sort By:
Clinical Therapeutics|September 23, 2006
Influence of culture site-specific MIC distributions on the pharmacokinetic and pharmacodynamic properties of piperacillin/tazobactam and piperacillin: a data analysisChristopher R Frei, Shanna L Hampton, David S Burgess
Infection and Drug Resistance|June 23, 2011
Micafungin in the treatment of invasive candidiasis and invasive aspergillosisNathan P Wiederhold, Jason M Cota, Christopher R Frei
Respirology (Carlton, Vic.)|December 20, 2015
Predictors of Pseudomonas and methicillin-resistant Staphylococcus aureus in hospitalized patients with healthcare-associated pneumoniaMark L Metersky, Christopher R Frei, Eric M Mortensen
ASM Case Reports|November 17, 2025
Successful clearance of persistent <i>Staphylococcus aureus</i> pneumonia with high-dose continuous infusion cefazolinAnnie A Smelter, Christopher R Frei, Dan F Smelter
Drugs|April 21, 2011
Fluoroquinolones in community-acquired pneumonia: guide to selection and appropriate useChristopher R Frei, Matthew J Labreche, Russell T Attridge
The Journal of Antimicrobial Chemotherapy|February 7, 2008
Antimicrobial breakpoints for gram-negative aerobic bacteria based on pharmacokinetic-pharmacodynamic models with Monte Carlo simulationChristopher R Frei, Nathan P Wiederhold, David S Burgess
American Journal of Infection Control|November 26, 2013
Trends in catheter-associated urinary tract infections among a national cohort of hospitalized adults, 2001-2010Kelly R Daniels, Grace C Lee, Christopher R Frei
Clinical Therapeutics|January 11, 2005
Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamasesLeticia R Moczygemba, Christopher R Frei, David S Burgess
International Journal of Antimicrobial Agents|July 21, 2005
Pharmacodynamics of intermittent and continuous infusion piperacillin/tazobactam and cefepime against extended-spectrum beta-lactamase-producing organismsAlicia M Reese, Christopher R Frei, David S Burgess
Federal Practitioner : for the Health Care Professionals of the VA, Dod, and PHS|September 20, 2023
Outcomes in Patients With Curative Malignancies Receiving Filgrastim as Primary ProphylaxisTerra Furney, Amy Horowitz, John Malamakal, et al.
Pageof 13

Showing results (11-20 of 127) with videos related to

Sort By:
Pageof 13
Clinical Therapeutics|September 23, 2006
Influence of culture site-specific MIC distributions on the pharmacokinetic and pharmacodynamic properties of piperacillin/tazobactam and piperacillin: a data analysisChristopher R Frei, Shanna L Hampton, David S Burgess
Infection and Drug Resistance|June 23, 2011
Micafungin in the treatment of invasive candidiasis and invasive aspergillosisNathan P Wiederhold, Jason M Cota, Christopher R Frei
Respirology (Carlton, Vic.)|December 20, 2015
Predictors of Pseudomonas and methicillin-resistant Staphylococcus aureus in hospitalized patients with healthcare-associated pneumoniaMark L Metersky, Christopher R Frei, Eric M Mortensen
ASM Case Reports|November 17, 2025
Successful clearance of persistent <i>Staphylococcus aureus</i> pneumonia with high-dose continuous infusion cefazolinAnnie A Smelter, Christopher R Frei, Dan F Smelter
Drugs|April 21, 2011
Fluoroquinolones in community-acquired pneumonia: guide to selection and appropriate useChristopher R Frei, Matthew J Labreche, Russell T Attridge
The Journal of Antimicrobial Chemotherapy|February 7, 2008
Antimicrobial breakpoints for gram-negative aerobic bacteria based on pharmacokinetic-pharmacodynamic models with Monte Carlo simulationChristopher R Frei, Nathan P Wiederhold, David S Burgess
American Journal of Infection Control|November 26, 2013
Trends in catheter-associated urinary tract infections among a national cohort of hospitalized adults, 2001-2010Kelly R Daniels, Grace C Lee, Christopher R Frei
Clinical Therapeutics|January 11, 2005
Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamasesLeticia R Moczygemba, Christopher R Frei, David S Burgess
International Journal of Antimicrobial Agents|July 21, 2005
Pharmacodynamics of intermittent and continuous infusion piperacillin/tazobactam and cefepime against extended-spectrum beta-lactamase-producing organismsAlicia M Reese, Christopher R Frei, David S Burgess
Federal Practitioner : for the Health Care Professionals of the VA, Dod, and PHS|September 20, 2023
Outcomes in Patients With Curative Malignancies Receiving Filgrastim as Primary ProphylaxisTerra Furney, Amy Horowitz, John Malamakal, et al.
Pageof 13